drugset

drugset / Trial / NCT04870372

Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease

NCT04870372 ↗

Phase 4 Completed 141 enrolled Second Affiliated Hospital of Soochow University

NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open-label, single-arm 8-week investigation of Selegiline for treatment of EDS in PD patients.

Timeline

Start: 2020-03-01
Primary completion: 2020-12-31
Completion: 2021-04-30

Publications

Background Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD. Development of excessive daytime sleepiness in early Parkinson disease. Neurology. 2015 Jul 14;85(2):162-8. doi: 10.1212/WNL.0000000000001737. Epub 2015 Jun 17.
Background Panisset M, Stril JL, Belanger M, Lehoux G, Coffin D, Chouinard S. Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline. Can J Neurol Sci. 2016 Nov;43(6):809-814. doi: 10.1017/cjn.2016.289.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selegiline	Unknown	10 mg	—

Indications